Reply to SGLT-2 inhibitors: Post-infarction interventional effects

Pasquale Paolisso; Luca Bergamaschi; Felice Gragnano; Emanuele Gallinoro; Arturo Cesaro; Celestino Sardu; Niya Mileva; Alberto Foà; Matteo Armillotta; Angelo Sansonetti; Sara Amicone; Andrea Impellizzeri; Giuseppe Esposito; Nuccia Morici; Oreglia Jacopo Andrea; Gianni Casella; Ciro Mauro; Dobrin Vassilev; Nazzareno Galie; Gaetano Santulli; Raffaele Marfella; Paolo Calabrò; Emanuele Barbato; Carmine Pizzi

doi:10.1016/j.phrs.2023.106664

Reply to SGLT-2 inhibitors: Post-infarction interventional effects

Pharmacol Res. 2023 Mar:189:106664. doi: 10.1016/j.phrs.2023.106664. Epub 2023 Jan 13.

Authors

Pasquale Paolisso¹, Luca Bergamaschi², Felice Gragnano³, Emanuele Gallinoro⁴, Arturo Cesaro³, Celestino Sardu⁵, Niya Mileva⁶, Alberto Foà², Matteo Armillotta², Angelo Sansonetti², Sara Amicone², Andrea Impellizzeri², Giuseppe Esposito⁷, Nuccia Morici⁸, Oreglia Jacopo Andrea⁹, Gianni Casella¹⁰, Ciro Mauro¹¹, Dobrin Vassilev¹², Nazzareno Galie², Gaetano Santulli¹³, Raffaele Marfella¹⁴, Paolo Calabrò³, Emanuele Barbato¹⁵, Carmine Pizzi¹⁶

Affiliations

¹ Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
² Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy.
³ Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy; Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
⁴ Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
⁵ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
⁶ Cardiology Clinic, "Alexandrovska" University Hospital, Medical University of Sofia, Sofia, Bulgaria.
⁷ Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Interventional Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.
⁸ IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy.
⁹ Interventional Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.
¹⁰ Unit of Cardiology, Maggiore Hospital, Bologna, Italy.
¹¹ Department of Cardiology, Hospital Cardarelli, Naples, Italy.
¹² Medica Cor Hospital, Russe, Bulgaria.
¹³ Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy; International Translational Research and Medical Education (ITME) Consortium, Naples, Italy; Department of Medicine (Division of Cardiology) and Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, New York, USA.
¹⁴ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy; Mediterranea Cardiocentro, Naples, Italy.
¹⁵ Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.
¹⁶ Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy. Electronic address: [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Infarction
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents

Grants and funding

R01 HL146691/HL/NHLBI NIH HHS/United States